ViewRay Inc has announced that it has received regulatory approval from the Ministry of Food and Drug Safety, formerly known as the Korean Food and Drug Administration, to sell its ViewRay MRIdian MRI-guided radiation system in Korea.
The first patient treatments took place at Seoul National University Hospital (SNUH) on October 13, 2015, less than 4 weeks after the system completed installation, for a patient with a single liver metastasis. The ViewRay system was used to treat the patient with stereotactic body radiation therapy, because the system offers the accuracy and real-time MRI imaging during treatment to deliver the required high doses to the target, while minimizing damage to the surrounding healthy tissue.
“Receipt of Korean regulatory approval and the completion of the first international patient treatment are exciting milestones for us as we work to bring the benefits of MRI-guided radiation therapy to patients around the world,” said Chris A. Raanes, president and chief executive officer of ViewRay. “We are particularly pleased with how quickly and easily the system went from installation to first patient treatment.”
For more information about the MRIdian MRI-guided system, visit the ViewRay website.